



## SCIENTIFIC PROGRAMME

### Wednesday 23 September 2020

#### Health Professionals Programme

11:15 – 12:45

Health Professionals Kick-off Meeting



#### Working Party Meeting

11:15 – 12:45

PRes Working Party Meeting VACCINATION



#### Working Party Meeting

11:15 – 12:45

PRes Working Party Meeting JSLE



#### Side Meeting

11:15 – 12:45

Education and training Committee



#### Plenary

13:00 – 14:00

Opening ceremony, Barbara Ansell Lecture by Dan Kastner

13:00 - 13:05

**Welcome address** Berent Prakken (NL)

13:05 - 13:15

**E-Welcome** Lucy Wedderburn (UK)

13:15 - 13:20

**ENCA Chair** Wendy Costello (IR)

13:20 - 13:25

**Health Professionals Chair** Jeannette Cappon (NL)

13:25 - 13:30

**Intro of Ansell Keynote lecture** Lucy Wedderburn (UK)

13:30 - 13:50

**Rheumatic Disease and the Human Experience** Daniel Kastner (US)



#### State-of-the-Art Blended Session

14:30 – 15:30

A year in review in clinical and basic science

14:30 - 14:32

**Intro for speaker** Lucy Wedderburn (UK)

14:32 - 14:52

**Year in review clinical** Athimalaipet Ramanan (UK)

14:52 - 14:54

**Intro for speaker** Lucy Wedderburn (UK)

14:54 – 15:14

**Year in review basic and translational science** Peter Nigrovic (US)



*Note: all times are Central European Time*

15:14 - 15:16

**Intro for prize winner**

15:16 - 15:22

**YIM Winner (clinical science)**

15:22 - 15:24

**Intro for prize winner**

15:24 - 15:30

**YIM winner (Basic and translational science)**

### COVID Session

**16:00 – 17:00**

**COVID phenotypes in children**

*Moderator: Athimalaipet Ramanan*

16:00 - 16:15

**COVID in teenagers and adults: hyperinflammation across the spectrum** *Rachel Tattersall (UK)*

16:15 - 16:20

**Discussion**

16:20 - 16:35

**Paediatric multi system inflammatory syndrome (PIMS-TS):**

**what is it, who gets it and how to manage it (aka, “KD or not KD”)** *Liz Whittacker (UK)*

16:35 - 16:40

**Discussion**

16:40 - 16:55

**Why are many children only mildly affected or asymptomatic when their immune system meets SARS-2?** *George Kassiotis (UK)*

16:55 - 17:00

**Discussion**

### Sponsored Symposium

**17:15 – 18:15**

**Please check dedicated page on website for further details**

### Working Party Meeting

**17:15 – 18:15**

**PRs Working Party Meeting IMAGING**

### Clinical and Practice Track

**18:15 – 19:10**

**JIA from around the world**

18:15 - 18:25

**Cases of difficult JIA** *Lovro Lamot (CR)*

18:25 - 18:40

**Clinical trials – what they tell us and what they don’t** *Tim Beukelman (US)*

18:40 - 18:55

**How I manage refractory JIA – developed country perspective** *Fabrizio de Benedetti (IT)*

18:55 - 19:10

**How I manage refractory JIA – developing country perspective** *Sathish Kumar (IN)*

### Basic and Translational Track

**18:15 – 19:00**

**Big data: from single cells to new treatments?**

18:15 - 18:30

**Using big data to understand the immune system** *Adrian Liston (UK)*

18:30 - 18:45

**From single cell data to patient benefit: the AMP project** *Kazu Ishigaki (US)*

18:45 - 19:00

**Using high dimensional genomics to repurpose drugs** *Gisella Orozco (UK)*

### ENCA Programme

18:15 – 19:15

**Patient research education**

*Moderator: Christophe Normand (FR)*

18:15 - 18:30

**Patient involvement in research** *Vincent Del Gazio (CA)*

18:30 - 18:45

**Research: practical tips** *Richard Beesley (UK)*

18:45 - 19:15

**Discussion** *Christophe Normand (FR)*



### Health Professionals Programme

18:15 – 19:00

**Physical activity & physical fitness in children with rheumatic diseases**

18:15 - 18:30

**Physical fitness and Physical activity levels in JIA** *Kristine Risum (NO)*

18:30 - 18:45

**Benefits of Pilates for children with JIA** *Gregor Kuntze (CA)*

18:45 - 19:00

**Serious gaming in exercise programs for children with RD** *Nilay Arman (TR)*

### Meet the Professor

18:15 – 19:15

**Interactive discussion with experts**

**Building a Paediatric Rheumatology Team** *Ron Laxer (CA)*



### Sponsored Symposium

19:30 – 20:00

**Meet the Expert: Dirk Föll**



## Thursday 24 September 2020

### Clinical and Practice Track

09:30 – 10:25

**ERA and imaging**

09:30 - 09:40

**Difficult case (s) of ERA** *Erdal Sag (TR)*

09:40 - 09:55

**Arthritis with enthesitis and/or sacroiliitis in children** *Miroslav Harjacek (CR)*

09:55 - 10:10

**Treatment of the child with enthesitis and/or sacroiliitis: when to start biologics** *Mara Becker (US)*

10:10 - 10:25

**Advances in imaging of sacroiliitis and enthesitis: from X-ray to MRI and ultrasound** *Nele Herregods (BE)*

### Basic and Translational Track

09:30 – 10:15

#### Immuno-metabolism

09:30 - 09:45

**ROS and Metabolism: Regulation of Inflammation by T cells** Dirk Brenner (LU)

09:45 - 10:00

**T cell immune metabolism in JIA** Enric Mocholi (NL)

10:00 - 10:15

**Metabolic 'training' of the innate immune system** Jorge Domínguez-Andrés (NL)

### Health Professionals Programme

09:30 – 10:30

#### Coping with disease: tears, fears & needles

09:30 - 09:45

**Supporting coping and self-management in transition** Margot Walter (NL)

09:45 - 10:00

**Eye movement desensitization (EMDR) for MTX intolerance** Boris Hugel (GE)

10:00 - 10:15

**Children with JIA: experience of using Entonox for intra-articular joint injections** Norma O Keefe (IR)

10:15 - 10:30

**Lived experience of JDM: the young persons perspective** Polly Livermore (UK)

### Side meetings

09:30 – 10:30

#### ERN RITA session: Rare immunodeficiency, autoimmunity and autoinflammation

Moderator: Joost Frenkel (NL)

09:30 - 09:45

**RITA's deranged immune system** Mark Little (IR)

09:45 - 09:50

#### Discussion

09:50 - 10:05

**Genotype-phenotype correlation of cutaneous manifestations: Never-ending story of (auto)inflammation** Marc Jansen (NL)

10:05 - 10:10

#### Discussion

10:10 - 10:25

**Neonatal hyperinflammation: Sepsis, HLH or periodic fever?** Sarka Fingerhutova (CZ)

10:25 - 10:30

#### Discussion

### Meet the Professor

09:30 – 10:30

#### Interactive discussion with experts

**How to combine research with clinical career and be highly successful** Nico Wulffraat

### Meet the Professor

09:30 – 10:30

#### Interactive discussion with experts

**Training of Paediatric Rheumatology in a resource stretched environment** Raju Khubchandani

### ENCA Programme

11:15 – 12:15

**Social Media for families**

11:15 - 11:30

**Using social media to engage with your community** *Simon Stones (UK)*

11:30 - 11:40

**Virtual expert panel introductions** *Veerle Buys (BE), Monique Gore-Massy (US), Sarah Edwards (UK)*

11:40 - 12:10

**Discussion**

12:10 - 12:15

**Summary**

**Working Party Meeting**

11:15 – 12:45

**PRs Working Party Meeting AUTOINFLAMMATION**



**Working Party Meeting**

11:15 – 12:45

**PRs Working Party Meeting JDM**



**Working Party Meeting**

11:15 – 12:45

**PRs Working Party Meeting UVEITIS**



**Sponsored symposium**

13:00 – 14:00

**Please check dedicated page on website for further details**



**PRINTO**

13:00 – 14:00

**PRINTO General Assembly**



**Lightning talks and e-posters viewing**

14:00 – 15:30




• **Autoinflammatory and bone disease**

*Moderator: Bas Vastert (NL)*



- O001** CLINICAL FEATURES AND OUTCOMES IN STING-ASSOCIATED VASCULOPATHY WITH ONSET IN INFANCY (SAVI) / S. Torreggiani
- O002** COMPARISON OF CLINICAL AND IMAGING FEATURES BETWEEN CHRONIC NONBACTERIAL OSTEOMYELITIS AND ITS MIMICKERS: A MULTI-NATIONAL 450 CASE-CONTROL STUDY / Y. Zhao
- O003** DEMOGRAPHIC FEATURES IN A COHORT OF 101 CHILDHOOD ONSET FMF PATIENTS WITH RENAL AMYLOIDOSIS / Z. Arici
- O004** EVALUATION OF THE NEW CLASSIFICATION CRITERIA FOR PFAPA SYNDROME / A. Fouriki
- O005** GUT MICROBIOTA PROFILING OF CHILDREN AFFECTED BY CHRONIC NONBACTERIAL OSTEOMYELITIS (CNO): A POTENTIAL ROLE IN THE PATHOGENESIS / M. Capponi
- O006** CHARACTERISATION OF A GROUP OF PATIENTS WITH PSTPIP1-ASSOCIATED INFLAMMATORY SYNDROME / Z. Nesterenko



- O007** BASELINE CHARACTERISTICS OF AN INTERNATIONAL LONGITUDINAL COHORT OF 1012 FMF PATIENTS FROM THE EUROFEVER REGISTRY / M. Bustaffa
- O008** THE LEVEL OF INTERFERON ALPHA PROTEIN IN DISTINCT INTERFERONOPATHIES PROVIDES CLUES TO THE OBSERVED DIFFERENTIAL TISSUE INVOLVEMENT / L. Lodi
- O009** STANDARDIZING CARE AND FOSTERING SYSTEMIC AUTOINFLAMMATORY DISEASE (SAID) RESEARCH THROUGH THE CARRA AUTOINFLAMMATORY DISEASE NETWORK / G. S. Schuler
- O010** EVALUATION OF THE THYROID DISORDERS IN CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER / M. Yildiz
- O011** GALECTIN-3: A NEW BIOMARKER FOR DIFFERENTIATING PFAPA (PERIODIC FEVER, ADENITIS, PHARYNGITIS, APHTHOUS STOMATITIS) SYNDROME FROM FAMILIAL MEDITERRANEAN FEVER / E. D. Batu
- O012** LONG-TERM EFFECTIVENESS OF CANAKINUMAB IN AID – INTERIM ANALYSIS OF THE CAPS SUBGROUP FROM THE RELIANCE REGISTRY / J. Kuemmerle-Deschner
- O013** CLINICAL, DIAGNOSTIC AND THERAPEUTIC FEATURES OF CHILDREN WITH CHRONIC NON-BACTERIAL OSTEOMYELITIS (CNO) – AN ANALYSIS OF THE GERMAN NATIONAL PEDIATRIC RHEUMATOLOGIC DATABASE 2009-2018 / C. Reiser
- O014** PAEDIATRIC SARCOIDOSIS: PHENOTYPE OF A RETROSPECTIVE COHORT OF BIOPSY-PROVEN PATIENTS / K. A. Nott
-  **LB006** RISK FACTORS OF PERSISTENTLY ACTIVE DISEASE AMONG FILIPINO CHILDREN WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: 10-YEAR STUDY IN A TERTIARY HOSPITAL / I. J. E. Alberca

- **Treatment**

*Moderator: Alessandro Consolaro (IT)*

- O015** TRANSITION READINESS ASSESSMENT FROM PEDIATRIC TO ADULT SERVICES IN RHEUMATIC DISEASES / S. Kittivisuit
- O016** EARLY IMPLEMENTATION OF TREATMENT WITH ETANERCEPT INCREASES THE LIKELIHOOD TO ACHIEVE REMISSION / J. Klotsche
- O017** SAFETY OF BIOLOGICALS IN JUVENILE IDIOPATHIC ARTHRITIS: A RISK ANALYSIS FROM THE BIKER REGISTER / G. Horneff
- O018** VACCINATION WORKING PARTY OF PRES- PAST, PRESENT AND FUTURE / N. Toplak
- O019** ATTAINMENT OF INACTIVE DISEASE FOLLOWING DISCONTINUATION OF ADALIMUMAB MONOTHERAPY IN PATIENTS WITH ERA / S. Papailiou
- O020** CANAKINUMAB, ON A REDUCED DOSE OR A PROLONGED DOSE INTERVAL WITHOUT CONCOMITANT CORTICOSTEROIDS AND METHOTREXATE, MAINTAINS CLINICAL REMISSION IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / P. Quartier
- O021** LONG-TERM SAFETY PROFILE OF ANAKINRA IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS / G. Giancane
- O022** EARLY TREATMENT AND IL1RN SNPS AFFECT RESPONSE TO ANAKINRA IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS / M. N. Rossi

- O023** PHARMACOKINETICS-PHARMACODYNAMICS OF HYDROXYCHLOROQUINE IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS / B. Bader-Meunier
- O024** 'IT GIVES THE TREATMENT STRUCTURE': PATIENT AND PARENTAL PERSPECTIVES ON TREATING TO TARGET IN JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS TREAT / E. M. Smith
- O025** A NATIONAL MULTICENTRE STUDY ON SEVERE PAEDIATRIC RECURRENT IDIOPATHIC PERICARDITIS TREATED WITH IL-1 BLOCKERS: APPROPRIATENESS OF THE STANDARD OF CARE AND PROS AND CONS OF ANTI-IL-1 TREATMENTS. / R. Caorsi
- O026** EVALUATION OF FLARE RATE AND TAPERING STRATEGIES IN JUVENILE IDIOPATHIC ARTHRITIS / A. García Fernández
- O027** SHOULD ETANERCEPT BE AVOIDED IN CERTAIN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS DUE TO RISK OF DEVELOPING INFLAMMATORY BOWEL DISEASE ? / R. M. Krol
- O028** EARLY START OF BIOLOGICAL TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS: DOES A THERAPEUTIC WINDOW EXIST IN REAL LIFE? / A. Garcia Fernandez
- O029** AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RHEUMATOLOGIC DISEASES: THE EXPERIENCE OF A THIRD-LEVEL HOSPITAL IN MEXICO. / S. Rodríguez Aguayo



**LB005** CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: CLINICAL INACTIVE DISEASE RATE AND SAFETY IN ITALIAN PATIENTS / A. De Matteis

- **Basic and translational science**

*Moderator: Klaus Tenbrock (GE)*

- O030** EXAMINING HEALTH OUTCOMES IN JUVENILE IDIOPATHIC ARTHRITIS- A GENETIC EPIDEMIOLOGY STUDY / S. L. N. Clarke
- O031** PATIENTS WITH PERIODIC FEVER, APHTHOUS STOMATITIS, PHARYNGITIS AND ADENITIS (PFAPA) SYNDROME HAVE DIFFERENTIAL METHYLATION IN INTRON REGIONS OF PIK3AP1 AND SPON2 GENES / E. Lovšin
- O032** CELL DAMAGE AND PATHOGEN-ASSOCIATED TLR4 LIGANDS FUNDAMENTALLY DIFFER IN THEIR ABILITY TO INDUCE TYPE I INTERFERON EXPRESSION / M. H. Tedy
- O033** SEX DIFFERENCES IN JUVENILE-ONSET SLE SUSCEPTIBILITY AND CARDIOVASCULAR RISK COULD BE ASSOCIATED WITH ALTERED TREG PHENOTYPE AND LIPOPROTEIN METABOLISM / G. A. Robinson
- O034** EXAMINING THE ROLE OF IFN-I AND LANGERHANS CELL ADAM17 IN LUPUS PHOTSENSITIVITY / K. Veiga
- O035** SYNOVIAL TISSUE RESIDENT MEMORY T CELLS MEDIATE ARTHRITIS FLARES / M. H. Chang
- O036** AN ACTIVE PRONGF/P75NTR AXIS IN ARTHRITIS PATIENTS INFLUENCES CYTOKINE PRODUCTION IN SYNOVIAL FIBROBLASTS / L. Farina
- O037** COEXISTENCE OF SYNOVIAL T LYMPHOCYTES DRIVING AND REGULATING CHRONIC INFLAMMATION IN JUVENILE IDIOPATHIC ARTHRITIS / T. Kallinich
- O038** IDENTIFICATION OF A REGULATORY PATHWAY GOVERNING EXPRESSION OF TRAF1 VIA A JIA-ASSOCIATED NON-CODING VARIANT / Q. Wang
- O039** A NOVEL LOSS-OF-FUNCTION MUTATION IN LACC1 UNDERLIES HEREDITARY JUVENILE ARTHRITIS WITH EXTENDED INTRA-FAMILIAL PHENOTYPIC HETEROGENEITY / Y. A. Butbul





- O040** ROLES OF INTESTINAL BARRIER AND MICROBE-ASSOCIATED MOLECULAR PATTERNS IN THE PATHOGENESIS OF INFLAMMATORY ARTHRITIS / J. Poline
  - O041** APPLICATION OF SYSTEMS BIOLOGY-BASED IN SILICO TOOLS TO OPTIMIZE TREATMENT STRATEGY IN STILL'S DISEASE / M. Coma
  - O042** INTERFERON- $\gamma$  DRIVES THE EXPRESSION OF T-BET IN NAÏVE B CELLS OF PATIENTS WITH PAEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS / E. Marasco
  - O043** IN VITRO ANALYSIS OF STANDARD OF CARE DRUGS ON THE IFN TYPE I SIGNATURE; ASPIRIN AND HYDROXYCHLOROQUINE THE OLD KIDS ON THE BLOCK / M. J. Wahadat
- 

• **Juvenile Idiopathic arthritis and uveitis**

*Moderator: Lovro Lamot (HR)*

- O044** SUBCHONDRAL HIGH T2 SIGNAL IN PEDIATRIC SACROILIAC JOINT MRI: A NORMAL FINDING THAT CAN MIMIC SACROILIITIS / N. Herregods
- O045** FOOT AND ANKLE MRI IN JIA: DEVELOPMENT AND PRELIMINARY VALIDATION OF A PAEDIATRIC-TARGETED MRI SCORING SYSTEM FOR THE ASSESSMENT OF DISEASE ACTIVITY AND DAMAGE. / C. Malattia
-  **O046** EARLY ACHIEVEMENT OF JADAS ACCEPTABLE DISEASE ACTIVITY IS STRONGLY PREDICTIVE OF ONE-YEAR REMISSION IN ETANERCEPT-TREATED POLYARTICULAR JIA PATIENTS: RESULTS FROM A BIKER COHORT / G. Armaroli
-  **O047** PATIENT-REPORTED ADVERSE EVENTS AND TREATMENT ADHERENCE IN JIA: ANALYSIS OF TWO LARGE INTERNATIONAL COHORTS / A. Alongi
- O048** TOFACITINIB FOR THE TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: PATIENT-REPORTED OUTCOMES IN A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED WITHDRAWAL STUDY / N. Ruperto
- O049** PREDICTORS OF CLINICAL REMISSION IN CHILDREN WITH EXTENDED OLIGOARTICULAR ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR PSORIATIC ARTHRITIS TREATED WITH ETANERCEPT IN THE CLIPPER STUDIES / J. Vojinović
- O050** EVALUATION OF ANTI-HBS AND ANTI-VZV ANTIBODY LEVELS IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS TREATED WITH CLASSICAL DISEASE MODIFYING DRUGS AND BIOLOGICS / Cicek
- O051** VALIDITY AND RELIABILITY OF FOUR PARENT/PATIENT REPORTED OUTCOME MEASURES FOR JUVENILE IDIOPATHIC ARTHRITIS / C. Trincianti
- O052** LONGITUDINAL EFFECTIVENESS OF ABATACEPT IN JUVENILE IDIOPATHIC ARTHRITIS (JIA): RESULTS FROM AN ONGOING JIA REGISTRY / N. Ruperto
- O053** DETERMINANTS OF DISCORDANCE BETWEEN CRITERIA FOR INACTIVE DISEASE AND LOW DISEASE ACTIVITY IN JUVENILE IDIOPATHIC ARTHRITIS / G. Giancane
- O054** CLINICAL OUTCOMES OF JUVENILE ARTHRITIS IN ADULthood: A SYSTEMATIC REVIEW / Y. Wang
- O055** RELATIONSHIP BETWEEN PHYSICAL ACTIVITY AND CHARACTERISTICS OF ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA): RESULTS FROM THE GERMAN PAEDIATRIC RHEUMATOLOGIC DATABASE / F. Milatz
- O056** INFLUENZA VACCINE UPTAKE AMONG JUVENILE IDIOPATHIC ARTHRITIS(JIA) PATIENTS: A MULTI-CENTRE CROSS-SECTIONAL STUDY / F. Dasoula





**O057** PREDICTING THE INDIVIDUAL RISK OF UVEITIS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: AN INTERNATIONAL MULTICENTER COHORT STUDY / J. W. van Straalen

**O058** PROPOSAL FOR A DAMAGE AND RESPONSE INDEX FOR ANA-POSITIVE NONINFECTIOUS ANTERIOR UVEITIS FROM THE MULTINATIONAL INTERDISCIPLINARY WORKING GROUP FOR UVEITIS IN CHILDHOOD GROUP (MIWGUC) / I. Foeldvari



**LB004** THE EFFECTIVENESS OF POST-ISOMETRIC MUSCLE RELAXATION IN CHILDREN AND ADOLESCENTS WITH ANKYLOSING SPONDYLITIS / O. A. Tikhoplav

• **Patient /parent experience, e-health and psychosocial issues**

*Moderator: Victoria Harbottle (UK)*

**O059** PROSPECTIVE OBSERVATIONAL STUDY ON VIDEO CONSULTATION (VC) IN PAEDIATRIC RHEUMATOLOGY - AN EXPERIENCE FROM MUMBAI, INDIA / R. P. Khubchandani

**O060** INTERNET AND SMARTPHONE-BASED ECOLOGICAL MOMENTARY ASSESSMENT AND PERSONALIZED TREATMENT ADVICE (PROFEEL) IN ADOLESCENTS WITH CHRONIC CONDITIONS: A FEASIBILITY STUDY / M. M. Nap-Van Der Vlist

**O061** EVALUATION OF EDUCATIONAL RESOURCES DESIGNED TO FACILITATE ACCESS TO CARE FOR CHILDREN WITH MUSCULOSKELETAL CONDITIONS / N. Smith

**O062** A REALIST APPROACH TO ELICITING THE INITIAL PROGRAMME THEORIES FOR THE SELF- AND SHARED-MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS BY CHILDREN, YOUNG PEOPLE, FAMILIES AND PROFESSIONALS INVOLVED IN THEIR CARE / S. R. Stones

**O063** PATIENTS PERSPECTIVES ON LIVING WITH A SYSTEMIC AUTOINFLAMMATORY DISEASE: IMPACT ON QUALITY OF LIFE / M. C. Marques

**O064** CLUSTER CONSORTIUM CHAMPIONS, AND THE IMPORTANCE OF PATIENT AND PARENT INVOLVEMENT AND ENGAGEMENT IN RESEARCH CONSORTIUMS / F. Dekaj

**O065** THE PERSPECTIVE OF PARENTS/CARERS ON VACCINATIONS IN CHILDREN AND YOUNG PEOPLE WITH RHEUMATIC AND AUTOINFLAMMATORY DISEASES: RESULTS OF AN INTERNATIONAL SURVEY / S. Angevare

**O066** THE COVID-19 EUROPEAN PATIENT REGISTRY: DEVELOPMENT OF A PATIENT-LED RHEUMATOLOGY REGISTRY / R. P. Beesley

**O067** PARENTING STRESS IN PARENTS OF CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / K. Mulligan

**O068** SOME ASPECTS OF THE PSYCHOEMOTIONAL STATE OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS. / A. Y. Spivakovskaya

**O069** DIAGNOSIS OF DEPRESSIVE DISORDERS IN CHILDREN WITH JUVENAL IDIOPATHIC ARTHRITIS / L. F. Bohmat - N. S. Shevchenko

**O070** RHEUMATIC DISEASES IN MEXICAN CHILDREN AND THEIR PSYCHOSOCIAL AND ECONOMIC IMPACT ON CAREGIVERS / F. García Rodríguez

**O071** BARRIERS AND FACILITATORS TO PHYSICAL ACTIVITY IN JUVENILE IDIOPATHIC ARTHRITIS (JIA): A SCOPING REVIEW. / L. Larkin



• **Systemic lupus erythematosus and scleroderma**

*Moderator: Sylvia Kamphuis (NL)*

- O072** UNDER DETECTION OF INTERSTITIAL LUNG DISEASE IN JUVENILE SYSTEMIC SCLEROSIS (JSSC) UTILIZING PULMONARY FUNCTION TESTS. RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT. / I. Foeldvari
- O073** CROSS-CULTURAL ADAPTATION AND VALIDATION OF THE LOCALISED SCLERODERMA QUALITY OF LIFE INSTRUMENT (LOSQI) IN JLS: A MULTICENTRE STUDY OF THE PRES SCLERODERMA WORKING PARTY IN COLLABORATION WITH MEMBERS OF THE CARRA SCLERODERMA WORKING GROUP / C. Pain
- O074** ISCHEMIC STROKE IN CHILDREN WITH SCLERODERMA EN COUPE DE SABRE. / M. S. Pavlova
- O075** RAYNAUD'S PHENOMENON IN CHILDREN: A SURVEY OF UK & IRELAND PRACTICE / C. Anderson
- O076** NO DISEASE PROGRESSION AFTER 36 MONTHS FOLLOW UP IN THE JUVENILE SYSTEMIC SCLERODERMA INCEPTION COHORT. / I. Foeldvari
- O077** LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) IS ASSOCIATED WITH REDUCED FLARE FREQUENCY AND DAMAGE ACCRUAL IN CHILDREN WITH JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS / E. M. Smith
- O078** DEVELOPING A STANDARDIZED CORTICOSTEROID DOSING REGIMEN IN PEDIATRIC PROLIFERATIVE LUPUS NEPHRITIS / N. Aljaberi
- O079** RENAL ACTIVITY INDEX FOR LUPUS NEPHRITIS DISTINGUISHES ACTIVE RENAL DISEASE AMONG CHILDHOOD SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / N. Aljaberi
- O080** NAILFOLD CAPILLARY ABNORMALITIES IN A CROSS-SECTIONAL STUDY IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS COMPARED WITH MATCHED HEALTHY CONTROLS / D. Schonenberg-Meinema
- O081** NEUROPSYCHIATRIC INVOLVEMENT IN JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE): DATA FROM THE UK JSLE COHORT STUDY / T. Giani
- O082** UTILIZATION OF ANTI-NUCLEAR ANTIBODY ANALYSIS IN TERTIARY PEDIATRIC CLINIC / N. Sahin
- O083** MEDICATION UTILIZATION AND RENAL BIOPSY PATTERNS IN CHILDHOOD-ONSET LUPUS NEPHRITIS IN THE CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE REGISTRY / E. A. Smitherman

**State-of-the-Art Blended Session**

**15:45 – 16:50**

**Lifestyle and inflammation**

*Moderator: Amita Aggarawal*

15:45 - 15:50

**Lifestyle and arthritis - a patient perspective** *Niamh Costello (IR)*

15:50 – 16:05

**How do early life events influence our immune system?** *Petter Brodin (SE)*

16:05 – 16:10

**Discussion**

16:10 - 16:25



**Microbiome/diet and arthritis** *Matt Brown (UK)*

16:25 - 16:30

**Discussion**

16:30 - 16:45

**The effects and benefits of exercise-**

**what type and how does it improve disease?** *Emmanuelle Rochette (FR)*

16:45 - 16:50

**Discussion**

### Clinical and Practice Track

**17:00 – 17:55**

**What is new in JDM and vasculitis**

17:00 - 17:10

**Difficult refractory JDM cases** *Annette van Royen (NL)*

17:10 - 17:25

**Current and New Treatments for JDM : what is the evidence base?** *Brian Feldman (CA)*

17:25 - 17:40

**Relapse and Remission in ANCA vasculitis** *Mark Little (IR)*

17:40 - 17:55

**Don't forget the "rare" vasculitides** *Pavla Dolezalova (CZ)*

### Basic and Translational Track

**17:00 – 17:45**

**From genetics to mechanism**

17:00 - 17:15

**New genetic causes of highly inflammatory conditions** *Ivona Aksentijevich (US)*

17:15 - 17:30

**Mechanistic insights into early onset gout** *Blanka Stiburkova (CZ)*

17:30 - 17:45

**HLA-B27: Immune and non-immune effects in disease** *Bob Colbert (US)*

### COVID Session

**17:00 – 18:00**

**What have we learnt from COVID-19**

17:00 - 17:15

**The cytokine storm of COVID : what did MAS teach us?** *Grant Schuler (US)*

17:15 - 17:30

**Adapting practice in the COVID pandemic and beyond**

**– telemedicine and remote clinics** *Helen Foster (UK)*

17:30- 17:45

**How COVID disease affects immune suppressed**

**patients /clinical disease due to COVID in our patients ?** *Kimme Hrych (UK)*

17:45 - 18:00

**How parents and families reported experience of COVID** *Richard Beesley (UK)*

### Health Professionals/ENCA Programme

**17:00 – 18:00**

**Complex aspects of pain and fatigue in rheumatic diseases**

*Moderator: Janjaap Van der Net (NL)*

17:00 - 17:12



**Pain and fatigue in auto inflammatory disease: parent and patient** Saskya Angevare (NL)

17:12 - 17:15

**Discussion**

17:15 - 17:27

**The impact of pain and fatigue on psychosocial health** Angelo Ravelli (IT)

17:27 - 17:30

**Discussion**

17:30 - 17:42

**The role of the brain in pain experience: "It is in the head and it is real"** Andrew Segerdahl (UK)

17:42 - 17:45

**Discussion**

17:45 - 17:57

**Let's talk about pain": communication between**

**children, young people, parents and health professionals** Lis Cordingley (UK)

17:57 - 18:00

**Discussion**

### Side meetings

**17:00 – 18:00**

**Global task force**

17:00 - 17:15

**Gobal Health Task Force** Chris Scott (SA)

17:15 - 17:30

**Research Task Force** Brian Feldman (CA)

17:30 - 17:45

**Education Task Force** Annet van Royen (NL)

17:45 - 18:00

**Global Health Perspective** Soamarat Vilaiyuk (TH)

### Sponsored symposium

**18:30 – 19:30**

Please check dedicated page on website for further details



## Friday 25 September 2020

### Clinical and Practice Track

**09:30 – 10:15**

**Infection and arthritis**

09:30 - 09:45

**Autoimmunity in primary immune deficiency** Isabelle Meyts (BE)

09:45 - 10:00

**Infection while on biologics: what is the real risk ?** Joost Swart (NL)

10:00 - 10:15

**Infection and its significance in childhood arthritis** Angela Migowa (KE)

### Blended session

**09:30 – 10:45**

**Pediatric Rheumatology for the Pediatrician**

09:30 - 09:45

**Inflammatory Arthritis Early Identification and treatment: The most important part of Treating to Target**

Sefi Uziel (IL)

09:45 - 10:00

**Paediatric Musculoskeletal Examination for the Paediatrician: Better than any laboratory test**

*Mercedes Chan (CA)*

10:00 - 10:15

**Emergencies in Paediatric Rheumatology** *Petra Hissink Muller (NL)*

10:15 - 10:30

**Vasculitis for the Generalist: What to suspect- how to confirm- when to refer** *Seza Ozen (TR)*

**Meet the Professor**

09:30 – 10:30

Interactive discussion with experts

Spotting the rare among the common in paediatric Rheumatology *Seza Ozen*



**Working Party Meeting**

09:30 – 11:00

PRs Working Party Meeting MAS



**Health Professionals/ENCA Programme**

11:00 – 12:30

**What can YOU do about pain or fatigue?**

*Moderator: Sara Röstlund (SE)*

11:00 - 11:12

**Effective Interventions (evidence based) for pain in children with rheumatic diseases** *Maarten*

*Mensink (NL)*

11:12 - 11:15

**Discussion**

11:15 - 11:27

**Effective Interventions (experienced based by children and young people with rheumatic diseases) for pain and fatigue** *Simon Stones (UK)*

11:27 - 11:30

**Discussion**

11:30 - 11:42

**Effective interventions (Evidence based practice) for fatigue** *Johanna Kembe (SE)*

11:42 - 11:45

**Discussion**

→ **Move to next room**

11:45 – 12:05

**Break out in 3 small groups to discuss on “What can YOU do about pain and fatigue?”**

→ **Move to next room**

12:05 – 12:30

**Reconvene in full group**

**Working Party Meeting**

11:00 – 12:30

PRs Working Party Meeting SCLERODERMA



**Working Party Meeting**

11:00 – 12:30



**PRs Working Party Meeting VASCULITIS**

**State-of-the-Art Blended Session**

**12:45 – 13:50**

**Lupus across the ages**

12:45 - 12:55

**Patient: the experience of lupus as a young person** *Roopa Srinivasan (IN)*

12:55 - 13:10

**TLR7 evades silencing in human immune cells: connecting two X chromosomes with elevated risk of lupus** *Jean-Charles Guéry (FR)*

13:10 - 13:25

**New treatments for lupus: a breakthrough at last?** *Ronald Van Vollenhoven (NL)*

13:25 - 13:40

**Early onset forms of lupus : how does age influence phenotype in lupus?** *Alex Belot (FR)*

13:40 - 13:50

**How puberty impacts on the type I IFN axis: implications for lupus** *Kate Webb (SA)*

**PRs**

**14:30 – 15:45**

**PRs Annual General Assembly**



**Sponsored symposium**

**16:00 – 17:00**

**Please check dedicated page on website for further details**



**E-posters viewing**

**16:00 – 17:00**



**Clinical and Practice Track**

**17:00 – 17:50**

**New treatments on the horizon**

17:00 - 17:05

**The need for new treatments** *Wendy Costello (IE)*

17:05 - 17:20

**HOW Successful was repurposing of Rheumatology drugs for COVID?** *Xavier Mariette (FR)*

17:20 - 17:35

**IL-12, IL-17 and IL-23 blockade: for which patients and when to use them?** *Francesco Ciccia (IT)*

17:35 - 17:50

**Checkpoint inhibitors and how they unleash autoimmunity** *Andy Mammen (US)*

**Lightning talks and e-posters viewing**

**17:00 – 18:30**



- MAS and COVID-19**

*Moderator: Athimalaipet Ramanan (UK)*

**O084** HOW THE COVID-19 PANDEMIC HAS INFLUENCED PEDIATRIC RHEUMATOLOGY PRACTICE: RESULTS OF A GLOBAL, CROSS-SECTIONAL, ONLINE SURVEY / E. D. Batu

**O085** PAEDIATRIC MULTI-SYSTEM INFLAMMATORY SYNDROME TEMPORALLY ASSOCIATED WITH SARS-COV-2 MIMICKING KAWASAKI DISEASE (KAWA-COVID-19): A MULTICENTRE COHORT / I. Melki

- O086** ABSENCE OF SEVERE COMPLICATIONS FROM SARS-COV-2 INFECTION IN CHILDREN WITH RHEUMATIC DISEASES TREATED WITH BIOLOGIC DRUGS / F. Baldo
- O087** COVID-19 IN PEDIATRIC RHEUMATOLOGY PATIENTS TREATED WITH BIOLOGIC DRUGS: A CROSS-SECTIONAL, PATIENT SURVEY STUDY / M. Kasap Cuceoglu
- O088** STUDY OF EMAPALUMAB, A FULLY HUMAN, ANTI-IFN GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MAS/SHLH ON A BACKGROUND OF SJIA AND WITH INADEQUATE RESPONSE TO HIGH-DOSE GLUCOCORTICOIDS / F. De Benedetti
- O089** RISK SCORE OF MACROPHAGE ACTIVATION SYNDROME IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS / S. Carbogno
- O090** A PATIENT WITH IFNAR2 DEFICIENCY CAUSING DYSREGULATION OF NK CELL FUNCTIONS AND PRESENTING WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS /G. Prencipe
- O091** TRADITIONAL LABORATORY PARAMETERS AND NEW BIOMARKERS IN MACROPHAGE ACTIVATION SYNDROME (MAS) AND SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (SHLH) / A. De Matteis
- O092** MACROPHAGE ACTIVATION SYNDROME IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS: A SINGLE CENTER STUDY OF NINETEEN PATIENTS / I. Nikishina
- LB001** PEDIATRIC SYSTEMIC MULTI-INFLAMMATORY DISEASES IN ITALY DURING SARS-COV-2 EPIDEMIC: FROM KAWASAKI DISEASE TO KAWACOVID / M. Cattalini
- LB002** IMMUNOPATHOGENESIS OF COVID-19-RELATED PEDIATRIC INFLAMMATORY MULTISYSTEM SYNDROME: CYTOKINE PROFILE AND SARS-COV-2 SPECIFIC IMMUNE COMPLEXES / L. Alsina
- LB003** COVID-19 PANDEMIC - RELATED CHILBLAINS: CLINICAL AND IMMUNOLOGICAL CHARACTERIZATION OF AN ITALIAN COHORT / S. Signa
- 

- **Juvenile dermatomyositis and vasculitis**

*Pavla Dolezalova (CZ)*

- O093** EFFICACY AND SAFETY OF JAK INHIBITORS IN JUVENILE DERMATOMYOSITIS: A RETROSPECTIVE MONOCENTRIC STUDY / T. Le Voyer
- O094** ALTERED METABOLISM IN JUVENILE DERMATOMYOSITIS (JDM) MONOCYTES: A NEW THERAPEUTIC FOCUS IN JUVENILE DERMATOMYOSITIS / M. G. L. Wilkinson
- O095** BIOMARKERS GALECTIN-9 AND CXCL10 ARE OF ADDITIONAL VALUE IN THE CLINICAL DECISION-MAKING IN JUVENILE DERMATOMYOSITIS / S. R. Veldkamp
- O096** SIGLEC-1 EXPRESSION REFLECTS THE INTERFERON SIGNATURE IN JUVENILE DERMATOMYOSITIS AND DEFINES SUBCLASSES OF PATIENTS WITH DISTINCT INFLAMMATORY AND CLINICAL PROFILES / B. Lerkvaleekul
- O097** VALIDATION OF THE EULAR/ACR 2017 IDIOPATHIC INFLAMMATORY MYOPATHY CLASSIFICATION CRITERIA IN JDM PATIENTS / E. Sag
- O098** COMPARISON OF IVIG RESISTANCE PREDICTIVE MODELS IN KAWASAKI DISEASE / U. Kaya Akca





- O099** KAWANET-SCORE FOR PREDICTING RESISTANCE TO FIRST IMMUNOGLOBULINS IN KAWASAKI DISEASE: CONFIRMATION OF ITS GOOD SENSITIVITY AND PROPOSAL TO IMPROVE SPECIFICITY. / G. Beaujour
- O100** DIFFERENT HISTOLOGICAL CLASSIFICATIONS FOR HENOCH-SCHÖNLEIN PURPURA NEPHRITIS - WHICH ONE IS THE BEST PREDICTOR OF DISEASE OUTCOME? PILOT STUDY OF THE PRES VASCULITIS WORKING PARTY / M. Held - M. Sestan
- O101** A PILOT PROTEOMIC ANALYSIS OF PLASMA BIOMARKERS IN IGA VASCULITIS / S. Demir\*

#### Health Professionals Programme

**17:00 – 17:45**

**From research questions to recommendations in clinical care**

17:00 - 17:15

**Research agenda from the perspective of patient, care givers and healthcare professionals**

Wineke Armbrust (NL)

17:15 - 17:30

**EULAR Recommendation on Physical activity in adult arthritis : what can we learn?** Anne-Kathrin

Rausch Ophoff (CH)

17:30 - 17:45

**Benefits of implementation of Recommendations for patients** Maarten De Wit (NL)

#### Plenary

**18:45 – 19:30**

**Closing**

